☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Saxagliptin safety information

The manufacturer has written to healthcare professionals regarding new safety information for saxagliptin (Onglyza®).

The letter advises that saxagliptin has been associated with serious hypersensitivity reactions and acute pancreatitis. The following recommendations have now been made:

  • Saxagliptin is contraindicated in patients with a history of serious hypersensitivity reactions including anaphylactic reactions, anaphylactic shock and angioedema to saxagliptin or any other dipeptidyl peptidase 4 (DPP-4) inhibitor
  • Patients should be advised of the symptoms of acute pancreatitis and rapidly report such symptoms
  • Where hypersensitivity reactions or pancreatitis are suspected, saxagliptin should be discontinued

Action: Clinicians should be aware of this new safety information and implement any necessary changes to practice.

Share 'Saxagliptin safety information' by emailShare 'Saxagliptin safety information' on FacebookShare 'Saxagliptin safety information' on TwitterShare 'Saxagliptin safety information' on LinkedInShare 'Saxagliptin safety information' on reddit


No Comments to “Saxagliptin safety information”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.